The decay of the low-mode internal tide due to the superharmonic energy cascade is investigated in a realistically forced global Hybrid Coordinate Ocean Model (HYCOM) simulation with 1/25 degrees (4 km) horizontal grid spacing. Time-mean and depth-integrated supertidal kinetic energy is found to be largest near low-latitude internal tide generation sites, such as the Bay of Bengal, Amazon Shelf, and Mascarene Ridge. The supertidal kinetic energy can make up to 50% of the total internal tide kinetic energy several hundred kilometers from the generation sites. As opposed to the tidal flux divergence, the supertidal flux divergence does not correlate with the barotropic to baroclinic energy conversion. Instead, the time-mean and depth-integrated supertidal flux divergence correlates with the nonlinear kinetic energy transfers from (sub)tidal to supertidal frequency bands as estimated with a novel coarse-graining approach. The regular spaced banding patterns of the surface-intensified nonlinear energy transfers are attributed to semidiurnal mode 1 and mode 2 internal waves that interfere constructively at the surface. This causes patches where both surface tidal KE and nonlinear energy transfers are elevated. The simulated internal tide off the Amazon shelf steepens significantly near these patches, generating solitary-like waves in good agreement with Synthetic Aperture Radar (SAR) imagery. Globally, we find that regions of high supertidal energy flux also show a high correlation with observed instances of solitary nonlinear internal waves.

The potency and challenges of sorghum development in tidal swamplands in Indonesia have yet to be well studied. Our research was the first to evaluate land suitability, economic performance, and strategies for developing sorghum in tidal swamplands in Central Kalimantan. The assessment methods for the potency and utilization of sorghum used the land suitability evaluation method, gross margin and profit analysis, break-even, and competitive analysis. As a tool for decision-making, we used SWOT followed by the quantitative strategic planning matrix (QSPM) analysis. The results showed that the potency of arable land suitable for sorghum development was 578,511 ha. Economically, sorghum farming can generate an IDR 12,894,000 per ha with a revenue-cost ratio of 1.72; the break-even price was IDR 2,447 per kg, around 42% lower than the current market price. Sorghum was also more competitive than cassava, sweet potato, and soybeans (Q values of 0.76, 0.58, and 0.61, respectively) and less competitive than maize (Q = 1.33). Based on the QSPM, there were five alternative strategies for developing sorghum in tidal swamplands, i.e., (1) Optimization of productivity, (2) Improving the quality of human resources of farmers, (3) Facilitation of partnership cooperation, (4) Application of site-specific technology, and (5) Optimization of waste utilization. Those strategies show the potential expansion of sorghum planting in the tidal swamplands and the economic value enhancement for the community.

With the COVID-19 pandemic behind us, the U.S. Food and Drug Administration (FDA) has approved 55 new drugs in 2023, a figure consistent with the number authorized in the last five years (53 per year on average). Thus, 2023 is the second-best FDA harvest after 2018 (59 approvals) in all the series. Monoclonal antibodies (mAbs) continue to be the class of drugs with most approvals, with an exceptional 12, a number that makes it the most outstanding year for this class. As in 2022, five proteins/enzymes have been approved in 2023. However, no antibody–drug conjugate (ADC) has been released onto the market. With respect to TIDES (peptides and oligonucleotides), 2023 has proved a spectacular year, with a total of nine approvals, corresponding to five peptides and four oligonucleotides. Natural products continue to be the best source of inspiration for drug development, with 10 new products on the market. Three drugs in this year’s harvest are pegylated, which may indicate the return of pegylation as a method to increase the half-lives of drugs, after the withdrawal of peginesatide from the market in 2013. Following the trends of recent years, two bispecific drugs have been authorized in 2023. As in preceding years, fluorine and/or N-aromatic heterocycles are present in most of the drugs. Herein, the 55 new drugs approved by the FDA in 2023 are analyzed exclusively on the basis of their chemical structure. They are classified as the following: biologics (antibodies, proteins/enzymes); TIDES (peptide and oligonucleotides); combined drugs; pegylated drugs; natural products; nitrogen aromatic heterocycles; fluorine-containing molecules; and other small molecules.